Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Subtrial of KVD900 in Adolescents With Hereditary Angioedema
NCT05511922Phase 3Completed
- Sponsor
- KalVista Pharmaceuticals
- Start
- Oct 2022
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 17
01
Overview
A Phase 3 trial of sebetralstat in hereditary angioedema (HAE), sponsored by KalVista Pharmaceuticals. Started Oct 2022; status: completed.
02
Drugs
sebetralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT05511922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05511922.